Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Nature(2021)10.1038/s41586-021-03412-7Source: DataRank Database

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies is a research paper published in Nature (2021). On theSindex it has a DataRank of 0.986. It has been cited 717 times.

N/A

0.986DataRank · unranked

Scored on demand from live citation data

Open Access717 citations

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (21 grants)Impact (FWCI 42.63)OA: bronzeTopics (132)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.986

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (100)

Anna De Marco ORCID,Isabella A.T.M. Ferreira ORCID,Bo Meng ORCID,Rawlings Datir ORCID,Alexandra C. Walls ORCID

Live enrichment

PubMed:33706364 PMC:PMC7616976 OpenAlex:https://openalex.org/W3134446480

Wellcome Trust

Grant: 108082

National Institute for Health Research (NIHR)

Grant: ACF-2018-04-014

Academy of Medical Sciences

Grant: AMS-CSF4-Torok

National Institute for Health Research (NIHR)

Grant: NF-SI-0514-10109

Medical Research Council

Grant: MR/P008801/1

NIGMS NIH HHS

Grant: R01 GM120553

NIH HHS

Grant: S10 OD023476

Academy of Medical Sciences

Grant: SBF004\1052

Wellcome Trust

Grant: 108082/A/15/Z

Medical Research Council

Grant: MR/R008698/1

Investigating antibody affinity maturation during B cell exhaustion in viral infection

National Institute for Health Research (NIHR)

Grant: NIHR301445

Wellcome Trust

Grant: 200871/Z/16/Z

Cancer Research UK

Grant: 23923

NIAID NIH HHS

Grant: HHSN272201700059C

Medical Research Council

Grant: MC_PC_19027

Medical Research Council

Grant: MR/S00081X/1

Wellcome Trust

Grant: 204911/Z/16/Z

NIAID NIH HHS

Grant: DP1 AI158186

National Institutes of Health

Grant: 5R01GM120553-03

Structural Studies of Coronavirus Fusion Proteins

Wellcome Trust

Grant: 200871

A new biology of clinical outcome in immune-mediated disease

National Institutes of Health

Grant: 5DP1AI158186-05

Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeutics

FWCI

42.63

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

bronzeLicense: Springer TDM

journalhttps://www.nature.com/articles/s41586-021-03412-7.pdf

publisherhttps://www.nature.com/articles/s41586-021-03412-7.pdf

publisherhttps://www.nature.com/articles/s41586-021-03412-7

journalhttps://doi.org/10.1038/s41586-021-03412-7

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33706364

Fields of Study

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesViral gastroenteritis research and epidemiology0301 basic medicine03 medical and health sciencesAgedAged, 80 and overAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesFemaleHEK293 CellsHumansImmune EvasionImmunization, PassiveMaleMiddle AgedModels, MolecularMutationNeutralization TestsSARS-CoV-2Spike Glycoprotein, CoronavirusVaccines, SyntheticCOVID-19 SerotherapymRNA Vaccines

MeSH Terms

Angiotensin-Converting Enzyme 2COVID-19SARS-CoV-2COVID-19 VaccinesmRNA VaccinesCOVID-19 SerotherapyAgedAged, 80 and overAntibodies, MonoclonalAntibodies, ViralFemaleHumansImmunization, PassiveMaleMiddle AgedModels, MolecularMutationNeutralization TestsVaccines, SyntheticImmune EvasionAntibodies, NeutralizingHEK293 CellsSpike Glycoprotein, Coronavirus

Keywords

VirologyAntibodyMonoclonal antibodyNeutralizationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ReceptorBiologyNeutralizing antibodySpike ProteinMessenger RNAVirusCoronavirus disease 2019 (COVID-19)MedicineGeneImmunologyGeneticsInfectious disease (medical specialty)MaleModels, MolecularAngiotensin-Converting Enzyme 2 - metabolismPassiveSpike Glycoprotein, Coronavirus - geneticsSpike Glycoprotein, Coronavirus - metabolismAntibodies, ViralAntibodies, Viral - immunologyModelsMonoclonal80 and overViralNeutralizingCOVID-19 - therapySARS-CoV-2 - geneticsAged, 80 and overVaccinesVaccines, Synthetic - administration & dosageCOVID-19 Vaccines - immunologyAntibodies, MonoclonalC500Antibodies, Neutralizing - isolation & purificationMiddle AgedC700Spike GlycoproteinSpike Glycoprotein, CoronavirusFemalemRNA VaccinesSpike Glycoprotein, Coronavirus - chemistryAngiotensin-Converting Enzyme 2Aged; Aged, 80 and over; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Female; HEK293 Cells; Humans; Immune Evasion; Immunization, Passive; Male; Middle Aged; Models, Molecular; Mutation; Neutralization Tests; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccines, SyntheticCOVID-19 VaccinesSpike Glycoprotein, Coronavirus - immunologyAntibodies, Viral - isolation & purification610Immune Evasion - geneticsB100AntibodiesVaccines, Synthetic - immunologyNeutralization Tests616COVID-19 - virologyHumansSARS-CoV-2 - immunologyCOVID-19 - metabolismCOVID-19 SerotherapyAgedImmune EvasionQR355SARS-CoV-2SyntheticImmunization, PassiveMolecularAntibodies, Monoclonal - isolation & purificationCOVID-19Antibodies, Neutralizing - immunologyAntibodies, NeutralizingAntibodies, Monoclonal - immunologyCoronavirusHEK293 CellsImmune Evasion - immunologyCOVID-19 - immunologyMutationImmunization

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being